×
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
NYSE:BHVN

Biohaven Pharmaceutical Earnings Date, Estimates & Call Transcripts (2022)

$145.65
+1.23 (+0.85%)
(As of 06/29/2022 05:48 PM ET)
Add
Compare
Today's Range
$145.65
$146.59
50-Day Range
$83.14
$145.99
52-Week Range
$79.01
$151.51
Volume
1.79 million shs
Average Volume
1.21 million shs
Market Capitalization
$10.27 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$155.11

Earnings Summary

Upcoming
Earnings Date
Aug. 8Estimated
Actual EPS
(May. 10)
-$2.97 Missed By -$0.45
Consensus EPS
(May. 10)
-$2.52
Last Year's Q2 EPS
(5/9/2021)
-$4.21
Skip Charts & View Estimated and Actual Earnings Data

BHVN Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

BHVN Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Biohaven Pharmaceutical Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20224($3.59)($2.44)($2.96) 
Q2 20224($2.56)($1.97)($2.22) 
Q3 20224($2.08)($1.57)($1.89) 
Q4 20224($2.01)($1.33)($1.77) 
FY 202216($10.24)($7.31)($8.82) 
Q1 20232($1.96)($0.93)($1.45) 
Q2 20232($1.36)($0.40)($0.88) 
Q3 20232($0.54)($0.03)($0.29) 
Q4 20232($0.27)$0.22($0.03) 
FY 20238($4.13)($1.14) ($2.64)

BHVN Earnings Date and Information

Biohaven Pharmaceutical last announced its earnings results on May 10th, 2022. The reported ($2.97) EPS for the quarter, missing analysts' consensus estimates of ($2.52) by $0.45. Biohaven Pharmaceutical has generated ($11.84) earnings per share over the last year (($11.84) diluted earnings per share). Earnings for Biohaven Pharmaceutical are expected to grow in the coming year, from ($9.85) to ($5.68) per share. Biohaven Pharmaceutical has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 8th, 2022 based off prior year's report dates.

Biohaven Pharmaceutical Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
8/8/2022
(Estimated)
        
5/10/20223/31/2022($2.52)($2.97)($0.45)      
2/25/2022Q4 2021($2.07)($3.01)($0.94)($3.01)$175.54 million$190.01 million    
11/8/20219/30/2021($2.40)($2.63)($0.23)($2.63)$128.40 million$135.74 million    
8/8/20216/30/2021($2.77)($3.23)($0.46)($3.23)$85.85 million$92.93 million    
5/9/20213/31/2021($2.92)($4.21)($1.29)($4.21)$36.46 million$43.82 million    
2/28/202112/31/2020($2.89)($3.62)($0.73)($3.62)$35.01 million$35.10 million    
11/9/20209/30/2020($2.74)($3.27)($0.53)($3.27)$19.35 million$17.70 million    
8/10/20206/30/2020($2.78)($2.55)+$0.23($2.02)$7.43 million$9.70 million  
5/7/2020Q1($2.46)($2.39)+$0.07($1.71)$0.21 million$1.10 million
2/25/2020Q4($1.91)($2.85)($0.94)($2.85)
11/1/2019Q3 2019($1.57)($2.04)($0.47)($2.04)  
8/8/2019Q2($2.09)($2.35)($0.26)($0.03)  
5/7/20193/31/2019($1.50)($1.41)+$0.09($1.41)  
2/28/2019Q4 2018($1.28)($1.34)($0.06)($1.34)
11/14/20189/30/2018($1.05)($1.53)($0.48)($1.53)
8/14/2018Q2 2018($1.68)($1.01)+$0.67($1.01)
5/15/2018Q1 2018($1.1150)($2.32)($1.2050)($2.32)
3/6/2018Q4 2017($1.33)($0.75)+$0.58($0.75)
11/14/2017Q3 2017($1.22)($1.19)+$0.03($1.19)
8/14/2017Q2 2017($0.57)($1.78)($1.21)($1.78)
6/16/2017Q1 2017($0.88)($1.74)($0.86)($1.74)












Biohaven Pharmaceutical Earnings - Frequently Asked Questions

When is Biohaven Pharmaceutical's earnings date?

Biohaven Pharmaceutical has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 8th, 2022 based off last year's report dates. Learn more on BHVN's earnings history.

Did Biohaven Pharmaceutical beat their earnings estimates last quarter?

In the previous quarter, Biohaven Pharmaceutical (NYSE:BHVN) missed the analysts' consensus estimate of ($2.52) by $0.45 with a reported earnings per share (EPS) of ($2.97). Learn more on analysts' earnings estimate vs. BHVN's actual earnings.

How can I listen to Biohaven Pharmaceutical's earnings conference call?

The conference call for Biohaven Pharmaceutical's latest earnings report can be listened to online. Listen to Conference Call

How can I read Biohaven Pharmaceutical's conference call transcript?

The conference call transcript for Biohaven Pharmaceutical's latest earnings report can be read online. Read Transcript

How can I view Biohaven Pharmaceutical's earnings report?

Biohaven Pharmaceutical's earnings report can be found in their filing with the SEC. View SEC filing

How much revenue does Biohaven Pharmaceutical generate each year?

Biohaven Pharmaceutical (NYSE:BHVN) has a recorded annual revenue of $462.51 million.

How much profit does Biohaven Pharmaceutical generate each year?

Biohaven Pharmaceutical (NYSE:BHVN) has a recorded net income of -$846.59 million. BHVN has generated -$11.84 earnings per share over the last four quarters.

What is Biohaven Pharmaceutical's EPS forecast for next year?

Biohaven Pharmaceutical's earnings are expected to grow from ($9.85) per share to ($5.68) per share in the next year.

More Earnings Resources from MarketBeat

Upcoming Earnings:
This page (NYSE:BHVN) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.